Trevi Therapeutics, Inc.

Item 5. Other Information.

(c) Director and Officer Trading Arrangements

During the three months ended June 30, 2026, Jennifer Good, the Company's Chief Executive Officer, adopted a Rule 10b5-1 trading arrangement for the sale of common stock issuable upon the exercise of certain stock options held by Ms. Good. The trading agreement is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act. The stock options subject to this arrangement are scheduled to expire on December 20, 2027. This plan was adopted on June 11, 2026 and has an expiration date of December 31, 2026. Pursuant to the plan, the aggregate number of shares for which such options are to be exercised, and the aggregate number of shares of common stock to besold upon exercise of those options, is not to exceed 173,684.

During the three months ended June 30, 2026, Michael Heffernan, adirector of the Company, adopted a Rule 10b5-1 trading arrangement for the sale of common stock issuable upon the exercise of certain stock options held by Mr. Heffernan. The trading arrangement is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act. The stock options subject to this arrangement are scheduled to expire on February 27, 2027 and December 20, 2027, respectively. This plan was adopted on June 16, 2026 and has an expiration date of December 31, 2027. Pursuant to the plan, the aggregate number of shares for which such options are to be exercised, and the aggregate number of shares of common stock to besold upon exercise of those options, is not to exceed 39,473.

None of our other directors or officers adopted orterminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during thethree months ended June 30, 2026.